Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesGBR 1302 could be an out-licencing opportunity: Glenmark

SHOW NAMES

Trending Topics

business

GBR 1302 could be an out-licencing opportunity: Glenmark

GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.

first published: Aug 20, 2014 11:23 am

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell
Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live
Nifty Aims For Next 26,100 After Hitting 3-Week High |Opening Bell Live
Nifty Back Above 26,000 As IT Stocks Sprint Ahead; Nvidia Earnings In Focus| Closing Bell Live

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347